Evidence map›Paper›PMID 33790350›Full record

ArticleScientific reports2021

c-Jun N-terminal kinase 1 (JNK1) modulates oligodendrocyte progenitor cell architecture, proliferation and myelination.

Martina Lorenzati, Enrica Boda, Roberta Parolisi, Martino Bonato, Tiziana Borsello, Thomas Herdegen, Annalisa Buffo, Alessandro Vercelli

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Targeting JNK3: AnCNS & neurological disorders drug targets · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Cell morphologies in the nervous system: Glia steal the limelight.The Journal of comparative neurology · 2023
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Martina LorenzatiDepartment of Neuroscience Rita Levi-Montalcini, University of Turin, Turin, Italy.
Enrica BodaDepartment of Neuroscience Rita Levi-Montalcini, University of Turin, Turin, Italy.
Roberta ParolisiDepartment of Neuroscience Rita Levi-Montalcini, University of Turin, Turin, Italy.
Martino BonatoNeuroscience Institute Cavalieri Ottolenghi (NICO), University of Turin, Orbassano (Turin), Italy.
Tiziana BorselloIstituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.
Thomas HerdegenInstitute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany.
Annalisa BuffoDepartment of Neuroscience Rita Levi-Montalcini, University of Turin, Turin, Italy. annalisa.buffo@unito.it.
Alessandro VercelliDepartment of Neuroscience Rita Levi-Montalcini, University of Turin, Turin, Italy. alessandro.vercelli@unito.it.
Neuroscience Institute · ITUniversity of Turin · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During Central Nervous System ontogenesis, myelinating oligodendrocytes (OLs) arise from highly ramified and proliferative precursors called oligodendrocyte progenitor cells (OPCs). OPC architecture, proliferation and oligodendro-/myelino-genesis are finely regulated by the interplay of cell-intrinsic and extrinsic factors. A variety of extrinsic cues converge on the extracellular signal-regulated kinase/mitogen activated protein kinase (ERK/MAPK) pathway. Here we found that the germinal ablation of the MAPK c-Jun N-Terminal Kinase isoform 1 (JNK1) results in a significant reduction of myelin in the cerebral cortex and corpus callosum at both postnatal and adult stages. Myelin alterations are accompanied by higher OPC density and proliferation during the first weeks of life, consistent with a transient alteration of mechanisms regulating OPC self-renewal and differentiation. JNK1 KO OPCs also show smaller occupancy territories and a less complex branching architecture in vivo. Notably, these latter phenotypes are recapitulated in pure cultures of JNK1 KO OPCs and of WT OPCs treated with the JNK inhibitor D-JNKI-1. Moreover, JNK1 KO and WT D-JNKI-1 treated OLs, while not showing overt alterations of differentiation in vitro, display a reduced surface compared to controls. Our results unveil a novel player in the complex regulation of OPC biology, on the one hand showing that JNK1 ablation cell-autonomously determines alterations of OPC proliferation and branching architecture and, on the other hand, suggesting that JNK1 signaling in OLs participates in myelination in vivo.

Indexed as

Cell ProliferationMAP Kinase Signaling SystemAnimalsMiceMice, KnockoutMitogen-Activated Protein Kinase 8Myelin SheathOligodendrocyte Precursor CellsOligodendrogliaMitogen-Activated Protein Kinase 8

Identifiers

PMID33790350
PMCPMC8012703
OpenAlexW3141128048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.